Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.55 |
| ▸ | MPL | P40238 | 2/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626670 | 0.81 | C1S (0.46) | ALDH1A1MAPTKDM4EKDM1AC1S | |
| SCHEMBL12592159 | 0.79 | HSD17B10 (0.51) | ALDH1A1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL14988616 | 0.78 | KDM1A (0.64) | ALDH1A1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL19625513 | 0.77 | C1S (0.44) | ALDH1A1MAPTKDM1AC1S | |
| SCHEMBL13513656 | 0.77 | MAPT (0.59) | ALDH1A1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL713110 | 0.76 | HSD17B10 (0.61) | ALDH1A1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL13327639 | 0.76 | KDM1A (0.51) | ALDH1A1RAB9AMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL4381193 | 0.76 | CYP2A6 (0.54) | ALDH1A1MAPTKDM1ALMNACYP2C9 | |
| Bromide SCHEMBL8357463 | 0.75 | HSD17B10 (0.59) | ALDH1A1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL31603870 | 0.75 | KDM1A (0.44) | ALDH1A1MAPTHSD17B10KDM4EKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968577-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968577-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1283832-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| EP-1575502-B1 | COMPOSITIONS AND METHODS INVOLVING NUCLEAR HORMONE RECEPTOR SITE II | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7442554-B2 | Compositions and methods involving glucocorticoid receptor site II | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442554-B2 | Compositions and methods involving glucocorticoid receptor site II | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| WO-2008057862-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-7132436-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | CLARIO TECH LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| CN-1437588-A | 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | BIOVITRUM AB (SE) | 2003-08-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063051-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKB2, NFKBIA | ALDH1A1 4179/4885MEN1 3339/4885KMT2A 2852/4885 |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 55/4885MEN1 819/4885KMT2A 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.